Brazil has substantially expanded public oncology investment over the past decade, particularly within the Brazilian Unified Health System (SUS). However, whether increased spending has translated into measurable population‐level improvements in cancer outcomes remains uncertain.
Larissa Saldanha Fonseca, Leonardo Paredes Pires, L. Alencar et al.· Cancer Medicine· 0 citations
The evidence supports early integration of efficacy, mechanistic toxicology, CMC, and patient-specific risk rather than downstream safety testing alone, and indicates Harmonized characterization, clinically relevant models, long-term fate studies, and lifecycle surveillance remain central priorities for the next genera...
Taís Magne Ramos, L. Alencar, Eduardo Ricci-Júnior et al.· International Journal of Nan...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.